SG10201913501RA - Liposomal formulations - Google Patents

Liposomal formulations

Info

Publication number
SG10201913501RA
SG10201913501RA SG10201913501RA SG10201913501RA SG10201913501RA SG 10201913501R A SG10201913501R A SG 10201913501RA SG 10201913501R A SG10201913501R A SG 10201913501RA SG 10201913501R A SG10201913501R A SG 10201913501RA SG 10201913501R A SG10201913501R A SG 10201913501RA
Authority
SG
Singapore
Prior art keywords
liposomal formulations
liposomal
formulations
Prior art date
Application number
SG10201913501RA
Inventor
Subramanian Venkatraman
Yingying Huang
Amrita Nagle
Jayaganesh V Natarajan
Nicolas Daniel Marie Foin
Tze Tec Chong
Jie Liang Phua
Original Assignee
Univ Nanyang Tech
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nanyang Tech, Singapore Health Serv Pte Ltd filed Critical Univ Nanyang Tech
Publication of SG10201913501RA publication Critical patent/SG10201913501RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1277Processes for preparing; Proliposomes
    • A61K9/1278Post-loading, e.g. by ion or pH gradient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/0067Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0082Catheter tip comprising a tool
    • A61M25/0084Catheter tip comprising a tool being one or more injection needles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/10Balloon catheters
    • A61M25/104Balloon catheters used for angioplasty
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10201913501RA 2016-09-14 2017-09-14 Liposomal formulations SG10201913501RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG10201607641Q 2016-09-14

Publications (1)

Publication Number Publication Date
SG10201913501RA true SG10201913501RA (en) 2020-03-30

Family

ID=61619692

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913501RA SG10201913501RA (en) 2016-09-14 2017-09-14 Liposomal formulations
SG11201901097TA SG11201901097TA (en) 2016-09-14 2017-09-14 Liposomal formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201901097TA SG11201901097TA (en) 2016-09-14 2017-09-14 Liposomal formulations

Country Status (5)

Country Link
US (1) US20190216735A1 (en)
EP (1) EP3512503A4 (en)
CN (1) CN109789093A (en)
SG (2) SG10201913501RA (en)
WO (1) WO2018052373A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4015008A1 (en) 2018-05-17 2022-06-22 Hollister Incorporated Package containing hydrophilic urinary catheter and foamed hydration medium for its hydration
IT202000007228A1 (en) * 2020-04-06 2021-10-06 Diego Dolcetta ADMINISTRATION OF mTOR INHIBITORS IN THE CENTRAL NERVOUS SYSTEM

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
EP1159962A4 (en) * 1999-03-11 2003-07-02 Fujisawa Pharmaceutical Co Liposome preparations
NZ548195A (en) * 2004-01-14 2011-01-28 Gilead Sciences Inc Lipid-based dispersions useful for drug delivery
US20100129414A1 (en) * 2008-11-24 2010-05-27 Medtronic Vascular, Inc. Bioactive Agent Delivery Using Liposomes in Conjunction With Stent Deployment
EP2638896A1 (en) * 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
PL2992874T3 (en) * 2013-04-30 2019-01-31 Delta-Fly Pharma, Inc. Liposome for topical administration and application thereof

Also Published As

Publication number Publication date
CN109789093A (en) 2019-05-21
SG11201901097TA (en) 2019-03-28
EP3512503A4 (en) 2020-05-06
US20190216735A1 (en) 2019-07-18
WO2018052373A1 (en) 2018-03-22
EP3512503A1 (en) 2019-07-24

Similar Documents

Publication Publication Date Title
IL273541A (en) Formulations
IL268697A (en) Formulations
IL269630A (en) Niraparib formulations
IL269621A (en) Niraparib formulations
IL265609A (en) Novel formulations
GB201607918D0 (en) Novel formulations
IL273282A (en) Niraparib formulations
EP3265059A4 (en) Combination liposomal pharmaceutical formulations
GB201608356D0 (en) Formulation
SG10201913501RA (en) Liposomal formulations
HK1250338A1 (en) Liposomal adjuvant compositions
IL252955B (en) Mouthrinse formulations
GB201707615D0 (en) Formulation
GB201805338D0 (en) Cosmetic formulations
GB201621277D0 (en) Formulations
PL3559185T3 (en) Clear-rinse formulation
GB201618110D0 (en) Formulations
GB201616366D0 (en) Formulations
GB201615754D0 (en) Formulations
GB201714461D0 (en) Formulations
ZA201703472B (en) Mouthrinse formulations
GB201617866D0 (en) Novel formulations
GB201616509D0 (en) Novel formulations
GB201609925D0 (en) Formulation
GB201610440D0 (en) Pharmaceutical formulations